newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Provides R&D Update

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA) enabling preclinical studies